KODIAK SCIENCES INC (KOD) Fundamental Analysis & Valuation

NASDAQ:KOD • US50015M1099

24.86 USD
-0.3 (-1.19%)
At close: Mar 6, 2026
24.86 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This KOD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KOD. KOD was compared to 519 industry peers in the Biotechnology industry. While KOD seems to be doing ok healthwise, there are quite some concerns on its profitability. KOD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. KOD Profitability Analysis

1.1 Basic Checks

  • KOD had negative earnings in the past year.
  • In the past year KOD has reported a negative cash flow from operations.
  • In the past 5 years KOD always reported negative net income.
  • KOD had a negative operating cash flow in each of the past 5 years.
KOD Yearly Net Income VS EBIT VS OCF VS FCFKOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • KOD has a Return On Assets of -99.66%. This is in the lower half of the industry: KOD underperforms 75.00% of its industry peers.
  • With a Return On Equity value of -917.34%, KOD is not doing good in the industry: 79.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.66%
ROE -917.34%
ROIC N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
KOD Yearly ROA, ROE, ROICKOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KOD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOD Yearly Profit, Operating, Gross MarginsKOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. KOD Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, KOD has about the same amount of shares outstanding.
  • Compared to 5 years ago, KOD has more shares outstanding
  • KOD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KOD Yearly Shares OutstandingKOD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KOD Yearly Total Debt VS Total AssetsKOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -8.07, we must say that KOD is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of KOD (-8.07) is worse than 68.08% of its industry peers.
  • There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.07
ROIC/WACCN/A
WACCN/A
KOD Yearly LT Debt VS Equity VS FCFKOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • KOD has a Current Ratio of 1.78. This is a normal value and indicates that KOD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of KOD (1.78) is worse than 78.08% of its industry peers.
  • KOD has a Quick Ratio of 1.78. This is a normal value and indicates that KOD is financially healthy and should not expect problems in meeting its short term obligations.
  • KOD's Quick ratio of 1.78 is on the low side compared to the rest of the industry. KOD is outperformed by 77.12% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
KOD Yearly Current Assets VS Current LiabilitesKOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. KOD Growth Analysis

3.1 Past

  • KOD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.88%.
EPS 1Y (TTM)-12.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, KOD will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.83% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.28%
EPS Next 2Y-1.02%
EPS Next 3Y3.02%
EPS Next 5Y12.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOD Yearly Revenue VS EstimatesKOD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
KOD Yearly EPS VS EstimatesKOD Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. KOD Valuation Analysis

4.1 Price/Earnings Ratio

  • KOD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KOD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOD Price Earnings VS Forward Price EarningsKOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOD Per share dataKOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.02%
EPS Next 3Y3.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KOD Dividend Analysis

5.1 Amount

  • KOD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KOD Fundamentals: All Metrics, Ratios and Statistics

KODIAK SCIENCES INC

NASDAQ:KOD (3/6/2026, 8:00:02 PM)

After market: 24.86 0 (0%)

24.86

-0.3 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners92.78%
Inst Owner Change26.21%
Ins Owners4.78%
Ins Owner Change0%
Market Cap1.52B
Revenue(TTM)N/A
Net Income(TTM)-217.34M
Analysts80
Price Target36.21 (45.66%)
Short Float %11.98%
Short Ratio7.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.6%
Min EPS beat(2)-11.61%
Max EPS beat(2)4.42%
EPS beat(4)2
Avg EPS beat(4)-5.48%
Min EPS beat(4)-20.72%
Max EPS beat(4)5.97%
EPS beat(8)5
Avg EPS beat(8)-4.03%
EPS beat(12)7
Avg EPS beat(12)-2.61%
EPS beat(16)9
Avg EPS beat(16)-3.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.09%
PT rev (3m)99.07%
EPS NQ rev (1m)-2.62%
EPS NQ rev (3m)2.07%
EPS NY rev (1m)0.75%
EPS NY rev (3m)-3.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 64.01
P/tB 64.01
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.66%
ROE -917.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -8.07
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)491.62%
Cap/Depr(5y)1852.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
EPS Next Y-27.28%
EPS Next 2Y-1.02%
EPS Next 3Y3.02%
EPS Next 5Y12.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.4%
EBIT Next 3Y-10.91%
EBIT Next 5YN/A
FCF growth 1Y35.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.29%
OCF growth 3YN/A
OCF growth 5YN/A

KODIAK SCIENCES INC / KOD FAQ

What is the ChartMill fundamental rating of KODIAK SCIENCES INC (KOD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KOD.


What is the valuation status of KODIAK SCIENCES INC (KOD) stock?

ChartMill assigns a valuation rating of 0 / 10 to KODIAK SCIENCES INC (KOD). This can be considered as Overvalued.


What is the profitability of KOD stock?

KODIAK SCIENCES INC (KOD) has a profitability rating of 0 / 10.


How financially healthy is KODIAK SCIENCES INC?

The financial health rating of KODIAK SCIENCES INC (KOD) is 5 / 10.